Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRKU0L)

Drug Name

GS-5718 Drug Info

Synonyms

920036-34-6; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; 1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; SCHEMBL3606964; OKKLWSNHFSFXEM-UHFFFAOYSA-N; AMY21637; MFCD13183727; AKOS022178093; GS-5718; PB26872; CS-0048281; FT-0702852; A860172; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2	[1]
Cutaneous lupus erythematosus	EB5Z	Phase 1	[2]

Cross-matching ID

PubChem CID: 57443610
TTD Drug ID: DMRKU0L

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Renal carcinoma antigen NY-REN-64 (IRAK-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zabedosertib	DMEZGWP	Atopic dermatitis	EA80	Phase 2	[4]
CA-4948	DMWV8C6	Lymphoma	2A80-2A86	Phase 1	[5]
BAY1834845	DM8V62T	Psoriasis vulgaris	EA90	Phase 1	[6]
AZD6793	DM5GRZV	Inflammation	1A00-CA43.1	Phase 1	[7]
SAR444656	DMIF2OL	Atopic dermatitis	EA80	Phase 1	[8]
Pyrazolopyrimidine and thienopyrimidine amide derivative 1	DM6TB4Z	N. A.	N. A.	Patented	[9]
Pyrazolopyrimidine and thienopyrimidine amide derivative 2	DMFUNH4	N. A.	N. A.	Patented	[9]
Indazoletriazolephenyl derivative 1	DMHJDU6	N. A.	N. A.	Patented	[9]
Indazoletriazolephenyl derivative 2	DMWZLK6	N. A.	N. A.	Patented	[9]
Indazole amide derivative 2	DMRPT5O	N. A.	N. A.	Patented	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Renal carcinoma antigen NY-REN-64 (IRAK-4)	TTKFVXR	IRAK4_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05165771) A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 on Background Therapy With Conventional Synthetic Disease-modifying Antirheumatic Drug(s) (csDMARDs) in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04809623) A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects With Cutaneous Lupus Erythematosus (CLE). U.S.National Institutes of Health.
3	IRAK4 degrader to take on innate immunity. Nat Biotechnol. 2020 Nov;38(11):1221-1223.
4	Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Clinical pipeline report, company report or official report of AstraZeneca
8	Clinical pipeline report, company report or official report of Sanofi
9	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.